MHC I vs MHC II:
Key Differences
The main difference between MHC 1 and MHC 2 is the T-cell population they present peptides to: MHC class I is recognized by CD8+ T cells, whereas MHC class II is recognized by CD4+ T cells. They also differ in their usual antigen sources, cellular expression and peptide-binding structure. [1, 2, 3, 4]
MHC stands for major histocompatibility complex. In humans, MHC molecules are called human leukocyte antigens, or HLA. This comparison focuses on classical peptide-presenting MHC molecules and connects their biology to practical peptide and peptide-pool selection. [1, 2, 13]
MHC Class I vs Class II: Comparison Table
| Feature | MHC class I (MHC 1) | MHC class II (MHC 2) |
|---|---|---|
| T-cell recognition | CD8+ T cells; commonly associated with cytotoxic responses | CD4+ T cells; commonly associated with helper responses |
| Main cellular expression | Most nucleated cells | Mainly professional antigen-presenting cells: dendritic cells, macrophages and B cells |
| Usual antigen source | Intracellular proteins, including cytosolic and nuclear proteins | Proteins taken up into the endocytic pathway |
| Molecular structure | One membrane-spanning α heavy chain associated with β2-microglobulin | Two membrane-spanning chains: α and β |
| Peptide-binding groove | Closed at both ends; formed by the α1 and α2 domains | Open at both ends; formed by the α1 and β1 domains |
| Typical bound peptide length | Usually 8–11 amino acids; often 9 | Commonly about 13–25 amino acids, with a 9-residue binding core |
| Typical peptide-loading site | Endoplasmic reticulum (ER) | Endosomal or lysosomal compartments |
| Classical human HLA molecules | HLA-A, HLA-B and HLA-C | HLA-DP, HLA-DQ and HLA-DR |
| Important pathway exception | Cross-presentation of extracellular material | Presentation of intracellular material delivered through routes such as autophagy |
These are typical patterns, not absolute rules. Peptide lengths and expression vary with the molecule and biological context; the exceptions are explained below. [1, 2, 3, 4, 5, 6, 7, 9, 10, 13]
How MHC Structure Determines Peptide Binding
MHC class I: a closed groove for relatively short peptides
The MHC-I heavy chain forms the peptide-binding platform and associates with β2-microglobulin. The closed ends of its groove usually accommodate a relatively short peptide, with interactions near the peptide termini helping to stabilize binding. [1]
Nine amino acids is a useful reference length, not a universal requirement. Different HLA-I alleles have different sequence and length preferences, and longer ligands can be accommodated. Choosing every candidate as a 9-mer can therefore exclude relevant epitopes. [3]
MHC class II: an open groove with a binding core
MHC-II uses both an α chain and a β chain to form its groove. Because the ends are open, the bound peptide can extend beyond the groove. A central core of approximately nine residues mediates binding, while additional residues flank that core. [2, 4]
A longer peptide can contain more than one possible binding register: different stretches of its sequence may occupy the binding core. For class-II peptide selection, assess the relevant HLA molecule, core sequence and flanking residues rather than treating peptide length alone as evidence of suitability. [13]
Binding is not the same as a T-cell response. A candidate that binds an HLA molecule is not automatically a naturally presented antigen or a recognized T-cell epitope. Binding evidence, antigen processing and functional recognition answer different questions. [3, 13]
How Antigens Are Presented by MHC I and MHC II
Typical MHC-I route: Intracellular protein → proteasome processing → TAP transport into the ER → peptide loading → cell-surface presentation to CD8+ T cells.
Typical MHC-II route: Protein uptake → endosomal or lysosomal processing → peptide loading onto MHC-II → cell-surface presentation to CD4+ T cells.
In the conventional class-I pathway, intracellular proteins are degraded and resulting peptides can enter the ER through TAP, the transporter associated with antigen processing. Suitable peptides bind MHC-I before the complexes reach the cell surface. [5]
For class II, newly assembled molecules associate with the invariant chain, also called CD74. During trafficking through the endocytic pathway, invariant-chain degradation leaves CLIP in the groove. HLA-DM promotes CLIP removal and exchange for other peptides in acidic compartments. [6]
CD4 and CD8 are co-receptors, not the complete activation signal
The T-cell receptor recognizes the peptide–MHC complex, with CD8 or CD4 acting as the corresponding co-receptor. Productive activation also depends on cellular context. For example, CD28-mediated co-stimulation is a separate signal; displaying a peptide–MHC complex alone does not establish that a cell will successfully activate a T cell. [8]
Important Exceptions to the MHC-I/MHC-II Rules
The familiar “inside the cell versus outside the cell” explanation is a starting point, not a complete account of antigen presentation.
Cross-presentation: extracellular antigens on MHC class I
Dendritic cells can take up material from other cells and present derived peptides on MHC-I. This is called cross-presentation. It explains how an extracellular antigen source can contribute to a CD8+ T-cell response without following the simplest class-I pathway diagram. [9]
Intracellular antigens can also reach MHC class II
Autophagy can deliver intracellular proteins to compartments involved in MHC-II processing. Presentation of the Epstein–Barr virus nuclear antigen EBNA1 through this route provides an experimental example. MHC-II presentation is therefore not limited to proteins that originated outside the cell. [10]
MHC-II expression is not limited to three cell types
Dendritic cells, macrophages and B cells are the standard examples of professional antigen-presenting cells, but they are not the only cells that can express MHC-II. Thymic epithelial cells are an important example, and inflammatory signals such as interferon-γ can induce expression in other cellular contexts. [7]
Frequently Asked Questions
Scientific References
Primary studies supporting the scientific comparison and its experimental caveats. Some link labels are shortened for readability; linked records provide the full publication details.
- Bjorkman et al. (1987). Structure of the human class I histocompatibility antigen, HLA-A2. Nature.
- Stern et al. (1994). Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature.
- Trolle et al. (2016). Peptide length and allele-specific MHC-I binding preferences. J Immunol.
- Wang et al. (2008). Assessment of MHC class II peptide-binding predictions. PLoS Comput Biol.
- Früh et al. (1995). A viral inhibitor of peptide transporters for antigen presentation. Nature.
- Denzin and Cresswell (1995). HLA-DM, CLIP dissociation and MHC-II peptide loading. Cell.
- Waldburger et al. (2001). CIITA promoter IV and cell-specific MHC class II expression. J Exp Med.
- Jenkins et al. (1991). CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol.
- Albert, Sauter and Bhardwaj (1998). Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature.
- Paludan et al. (2005). Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science.
- Maecker et al. (2001). Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods.
- Draenert et al. (2003). Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J Immunol Methods.
- Jensen et al. (2018). Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology.
Can the same cell express both MHC class I and MHC class II?
Why are MHC-II peptides usually longer than MHC-I peptides?
Does an externally added peptide pool stimulate only CD4 T cells?
Does a positive pool response establish the HLA restriction?
Plan Your Peptide-Pool Project
Start with the antigen, intended T-cell readout and whether the question requires broad screening or defined epitopes. Explore existing PepMix™ pools or discuss a custom configuration for your project.